NCT03546868 is a Phase 2 clinical trial of [18F]FSPG in Inflammatory Bowel Diseases, sponsored by Asan Foundation.

Who is sponsoring NCT03546868?

NCT03546868 is sponsored by Asan Foundation.

What drugs are being tested in NCT03546868?

Interventions in NCT03546868: [18F]FSPG.

What condition does NCT03546868 study?

NCT03546868 studies Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease.

Is NCT03546868 still recruiting?

NCT03546868 is currently completed. Last updated 14 December 2020.

Last reviewed 2020-12-14 · How we verify

NCT03546868

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

Completed Phase 2 Last updated 14 December 2020

What this trial tests

Phase 2 trial testing [18F]FSPG in Inflammatory Bowel Diseases in 20 participants. Completed in 11 January 2019.

Timeline

14 August 2018

Primary endpoint
11 January 2019

11 January 2019

Quick facts

Lead sponsor	Asan Foundation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	14 August 2018
Primary completion	11 January 2019
Estimated completion	11 January 2019
Sites	2 locations across South Korea

Drugs / interventions tested

[18F]FSPG

Conditions studied

Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →
Ulcerative Colitis — all drugs for Ulcerative Colitis →
Crohn Disease — all drugs for Crohn Disease →

Sponsor

Asan Foundation

Who can join

Adults 19 to 79, any sex, with Inflammatory Bowel Diseases or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diagnostic validity of \[18F\]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease.
Rezazadeh F, Ramos N, Saliganan AD, Al-Hallak N, et al · · 2023 · cited 7× · PMID 37474270 · DOI 10.2967/jnumed.123.265649
PET Imaging of System x<sub>C</sub> <sup>-</sup> in Immune Cells for Assessment of Disease Activity in Mice and Patients with Inflammatory Bowel Disease.
Seo M, Kim Y, Ye BD, Park SH, et al · · 2022 · cited 7× · PMID 35086893 · DOI 10.2967/jnumed.121.263289
Imaging Agents for PET of Inflammatory Bowel Disease: A Review.
Rezazadeh F, Kilcline AP, Viola NT. · · 2023 · cited 6× · PMID 37918865 · DOI 10.2967/jnumed.123.265935

Verify or expand the search:

Other trials of [18F]FSPG

Trials testing the same drug.

NCT04488094 — Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation · Phase 2 · completed

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07033208 — Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance · NA · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting

Other Asan Foundation trials

Trials by the same sponsor.

NCT03112096 — A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease · Phase 1 · completed
NCT02864810 — Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03546868 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Foundation
Last refreshed: 14 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03546868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing